Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
  • Indications Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors BeiGene

    • Most Recent Events

    • 29 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
    • 08 Nov 2018 According to a Mirati Therapeutics media release, first patient has been dosed in the trial.
    • 08 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Mirati Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top